ArticleInfection and immunity1998
Susceptibility and serologic response of healthy adults to reinfection with Cryptosporidium parvum.
Article in Infection and immunity, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 183 citations in OpenAlex.
- Monitoring of cryptosporidiosis: a shift in circulatingEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Cryptosporidiosis in inborn errors of immunity: a single center cohort and review of the literature.The Journal of infectious diseases · 2026Article
- Human immune response to primary cryptosporidiosis parallels murine infection models.Infection and immunity · 2026Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Immunity to Cryptosporidium: insights into principles of enteric responses to infection.Nature reviews. Immunology · 2024Review
- Mining for crypto protection: a search for Cryptosporidium antibodies reveals antigens associated with immunity.The Journal of clinical investigation · 2023Article
- Article
- Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- An outbreak of cryptosporidiosis associated with drinking water in north-eastern Italy, August 2019: microbiological and environmental investigations.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- The enteric pathogeneLife · 2021Article
- Identification and characterization of a new 34 kDa MORN motif-containing sporozoite surface-exposed protein, Cp-P34, unique to Cryptosporidium.International journal for parasitology · 2021Article
- Successful experimental infant baboon model for childhood cryptosporidiosis studies.Parasites & vectors · 2021Article
- Nonsterile immunity to cryptosporidiosis in infants is associated with mucosal IgA against the sporozoite and protection from malnutrition.PLoS pathogens · 2021Article
- Opportunities and Challenges in Developing aACS infectious diseases · 2021Article
- A One Health Approach to Tackle Cryptosporidiosis.Trends in parasitology · 2020Review
- Review
- A Genetically Tractable, Natural Mouse Model of Cryptosporidiosis Offers Insights into Host Protective Immunity.Cell host & microbe · 2019Article
- Using thermodynamic parameters to calibrate a mechanistic dose-response for infection of a host by a virus.Microbial risk analysis · 2018Article
- Natural History of Cryptosporidiosis in a Birth Cohort in Southern India.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Cryptosporidium infection in solid organ transplantation.World journal of transplantation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Healthy adults are susceptible to infection with small numbers of Cryptosporidium parvum oocysts, resulting in self-limited infection. We investigated if infection of humans with C. parvum is protective 1 year after primary exposure. At 1 year after a primary challenge with 30 to 10(6) oocysts, 19 healthy immunocompetent adults were rechallenged with 500 oocysts and monitored for the development of infection and/or illness. Oocyst excretion was quantitated by direct immunofluorescence with a C. parvum-specific monoclonal antibody, and anti-C. parvum antibodies in serum were detected by an enzyme-linked immunosorbent assay. Fewer subjects shed oocysts after the second exposure (3 of 19; 16%) than after the first exposure (12 of 19; 63%) (P < 0.005). Although the rates of diarrhea were comparable after each of the two exposures, the clinical severity as determined by the mean number of unformed stools passed was lower after reexposure (11.25 versus 8.62; P < 0.05). The number of anti-Cryptosporidium immunoglobulin G and A seroconversions increased after secondary exposure. However, the C. parvum serum antibody response did not correlate with the presence or absence of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.